Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391196 · ClinicalTrials.gov registry record · Phase 3
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
NCT00391196 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 975 participants.
The verdict
NCT00391196, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
Interventions
- DRUG Placebo
- DRUG CP-945,598
- DRUG CP-945,598 Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391196
The ClinicalTrials.gov registry entry for NCT00391196 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00391196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00391196 about?
NCT00391196 is a clinical study titled "A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients". The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
What is the current status of trial NCT00391196?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2006-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00391196?
The interventions under investigation include: Placebo (DRUG), CP-945,598 (DRUG), CP-945,598 Treatment B (DRUG).
Who is sponsoring clinical trial NCT00391196?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.